HATFIELD, England, June 6, 2016 /PRNewswire/ --
FOR EMEA MEDIA ONLY: NOT FOR AUSTRIAN/SWISS/US MEDIA
Some people live up to four years after initiation of treatment with lenvatinib in differentiated thyroid cancer. Lenvatinib plus everolimus in kidney cancer also shows significantly improved progression free survival (PFS) compared with everolimus or lenvatinib alone according to new data presented at The American Society of Clinical Oncology Annual Meeting
Duration of overall response in people who receive Lenvima(R) (lenvatinib) is superior to placebo according to new efficacy data from the pivotal SELECT study. Updated results at longer follow-up also show that progression free survival (PFS) continues to improve for people with progressive radioactive iodine refractory differentiated thyroid cancer (RAI refractory DTC).
At the time of the primary analysis median duration of overall response was not reached. Today new efficacy data show that 157 patients (60.2%) respond to lenvatinib and the median duration of response is 30 months (95% CI 18.4-35.2), whereas three patients (2.3%) respond to placebo with a median duration of response of 14.7 months (95% CI 7.5-not evaluable [NE; median not yet reached]).
Median duration of overall response to lenvatinib is similar among all subgroups, except for patients with greater disease burden and patients with liver metastasis. Two patients, both with Hürthle cell variant thyroid cancer, remain on treatment with prolonged responses to lenvatinib. Both patients are alive almost four years after treatment initiation with lenvatinib, including one who has significant multiple metastases.
A statistically significant improvement in PFS continues to be seen at further follow-up for patients receiving lenvatinib compared with placebo (HR=0.24, 99% CI 0.17-0.35, p